Reuters logo
in 8 months
BRIEF-Revance initiates subject dosing in the sakura phase 3 clinical program of RT002
December 7, 2016 / 1:35 PM / in 8 months

BRIEF-Revance initiates subject dosing in the sakura phase 3 clinical program of RT002

1 Min Read

Dec 7 (Reuters) - Revance Therapeutics Inc -

* Revance announces initiation of subject dosing in the sakura phase 3 clinical program of RT002 injectable for the treatment of glabellar (frown) lines

* For RT002, there were no serious adverse events or evidence of any systemic exposure at any of three doses evaluated

* Topline results of pivotal efficacy trials anticipated in q4 2017

* Across all cohorts, RT002 appeared to be generally safe and well-tolerated Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below